Related Experiment Video
Updated: Jul 10, 2026

Methodology for Sputum Induction and Laboratory Processing
Published on: December 17, 2017
Levosalbutamol
1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz
Abstract:
Levosalbutamol is a chirally pure beta(2)-adrenoceptor agonist developed from racemic salbutamol. The therapeutically inactive (S)-enantiomer in racemic salbutamol may be associated with increased airway hyperreactivity in patients with asthma. Levosalbutamol aims to provide equivalent control of symptoms to salbutamol but without this potential unfavourable effect. The pharmacodynamic and pharmacokinetic profiles of levosalbutamol were similar to those of racemic salbutamol and no additional effects were reported. Levosalbutamol was bronchoprotective following a methacholine challenge. A large clinical study demonstrated that inhaled levosalbutamol, 0.625mg or 1.25mg 3 times daily, provided effective relief from the symptoms of asthma. Levosalbutamol 0.625mg was at least as effective as racemic salbutamol 2.5mg. Levosalbutamol was well tolerated in clinical trials and the risk/benefit ratio was reported to be superior to that of racemic salbutamol.
Related Concept Videos
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Adrenergic Agonists: Therapeutic Classification
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...

